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Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir
(ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation. Here,
we describe two further patients with chronic HBV infection who were found to develop the rtI233V mutation
after initiation of ADF therapy. These patients represent the first cases known so far in which the rtI233V ADF
resistance mutation evolved under persistent HBV replication during HBV therapy with ADF. Interestingly,
one of the previously described patients, who was initially successfully switched from ADF to tenofovir (TDF)
and became virologically suppressed subsequently, experienced a moderate but remarkable rebound of HBV
viremia after switching from TDF to entecavir, due to the emergence of renal toxicity. Thus, we provide evidence
for the selection and counterselection of the rtI233V ADF resistance mutation during antiviral therapy.
Despite safe and effective vaccines, chronic hepatitis B virus
(HBV) infection remains a major medical challenge, with an
estimated 350 million chronic carriers worldwide (19). These
patients have an increased risk for subsequent liver damage
that may lead to fibrosis, cirrhosis, and eventually hepatocel-
lular carcinoma (HCC) with a poor survival prognosis (7, 9).
The incidence of HCC correlates extremely well with the levels
of HBV viremia; indeed, the higher the HBV viral load is, the
higher the risk for HCC development becomes. Thus, a major
therapeutic goal in HBV therapy is reduction of viremia for
prevention of the emergence of fatal liver disease-related
events (2).
An increasing number of nucleoside and nucleotide ana-
logues that inhibit the reverse transcriptase (RT) activity of the
viral polymerase have been licensed for HBV therapy (5, 6).
That which became licensed was the nucleoside analogue lamiv-
udine (LAM), which has been extensively used ever since, due
to its impressive antiviral activity and clean safety profile. Un-
fortunately, the emergence of resistant mutant viruses under
LAM therapy substantially diminishes the long-term success of
this therapy. In 2003, the first nucleotide analogue, adefovir
(ADF), was licensed for HBV treatment (1, 11). ADF dis-
played a resistance profile superior to that of LAM while
maintaining an excellent antiviral activity. However, since its
approval, an increasing number of cases showing initial non-
response and clinical therapy failure have been reported, such as
those associated with the emergence of the rtN236T mutation
(13, 17, 18). One possible reason for an initial nonresponse to
ADF is infection with HBV variants harboring an rtI233V muta-
tion, which also confers resistance to ADF in vitro (15). This
variant has been detected in about 2% of all cases of naïve chronic
HBV carriers (2, 3).
In this report, we used previously published sequencing and
subspecies analyses (15) to further investigate, confirm, and
extend the significance of the rtI233V mutation in a clinical
setting. Our data further emphasize the necessity of HBV
genotyping prior to antiviral therapy for chronic hepatitis B.
We investigated two new, epidemiologically unrelated cases
showing resistance to ADF therapy due to the rtI233V muta-
tion. This is in contrast to the previously described cases in
which the rtI233V polymorphism was preexisting when ADF
therapy was initiated and failed thereafter (15). The first pa-
tient, referred to as patient 1, a Caucasian male, now 21 years
old, was first treated with LAM but subsequently was switched
to ADF after developing virological failure. Initially, HBV
viremia dropped significantly, from 108 genome equivalents
(GE)/ml to 2  104 GE/ml. However, since the viremia re-
mained at this relatively high level and the serum HBV surface
antigen (HBsAg) level increased significantly during therapy,
the case was considered to represent a therapy failure. To
determine the reason for this failure, quasispecies analysis of
the dominant HBV strain before and 24 months after initiation
of ADF therapy was performed. Quasispecies analysis was
performed by cloning products after PCR amplification of the
RT region of the viral polymerase and sequencing of up to 20
clones (4 representative clones are presented in Fig. 1). We
clearly identified the selection of resistance-associated muta-
tions in the dominant HBV population. The genotypic analysis
revealed genotype D and serotype ayw2, which converted to
ayw4 after 24 months of ADF treatment. The patient was
unsuccessfully pretreated with LAM and did not respond, most
probably as there was a minor population bearing the rtY203C
mutation, a known LAM resistance mutation (20). It was con-
cluded that this patient may have been a LAM nonresponder.
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Surprisingly, after 24 months of ADF treatment, sequencing
of the viral RT region revealed that the rtM204I mutation, a
well-known LAM resistance mutation (20), was present in vir-
tually all HBV subpopulations, whereas this mutation was not
detectable before ADF therapy. Furthermore, minor popula-
tions with the rtV173L and rtL180M mutations, both of which
are also associated with LAM resistance, were found after
ADF therapy (20). These findings were confirmed by direct
sequencing analysis of PCR products performed directly after
the patient was introduced to the outpatient clinic. The ob-
served type and frequency of these mutations are in agreement
with the results for the previous LAM therapy. However, a
delayed occurrence of the LAM-associated mutations after
replacement of LAM therapy with ADF therapy is unusual
and, to the very best of our knowledge, has not been described
so far. We can only speculate on the reasons for this phenom-
enon, which may be caused by a reduced viral fitness that may
be associated with the rtY203C mutation, but this would re-
quire further investigation and phenotypical characterization
of this variant. Most importantly, the rtI233V mutation was
present in all HBV subpopulations investigated after ADF
therapy but not in those investigated before ADF therapy. Our
findings thus clearly indicate that this mutation can develop
during or is selected by ADF therapy.
The second patient, referred to as patient 2, a 39-year-old
Caucasian male, was infected with HBV genotype D and se-
rotype ayw3, which changed to ayw4 after ADF therapy. He
was treated with ADF after failure of therapy with LAM.
During ADF therapy, the viral load initially decreased below
the limit of detection but within 3 months rose to 2  105
GE/ml, probably due to resistance development (Fig. 2). The
increase of HBV DNA was accompanied by an elevation of
HBsAg in the serum. Sequencing of the RT region of the HBV
genome revealed that the only mutation not detected prior to
ADF therapy and present in all clones was the rtI233V ADF
resistance mutation. This finding suggests efficient selection of
this resistance mutation under ADF therapy and corroborates
the findings for patient 1.
In conclusion, for both novel patients described in this re-
port, who developed ADF resistance during therapy, quasispe-
cies analyses revealed that the rtI233V mutation, a known
ADF resistance mutation, was present, whereas before ther-
apy, exclusively wild-type sequences were found in this region.
This result strongly supports the previous conclusions, drawn
from phenotypic analyses, that rtI233V mediates ADF resis-
tance in vivo.
Follow-up sera from two previously reported patients who
had been infected with HBV harboring rtI233V, which was
thus resistant to ADF, leading to treatment with tenofovir
(TDF), were investigated as described earlier (15). Clinical and
serological markers, like levels of HBsAg, viral load, and liver
enzymes, were monitored regularly during TDF treatment for
18 months. The female patient responded well to TDF treat-
ment, with a sustained virological response in which virus ge-
nome levels rapidly decreased from 5  108 genome equiv-
alents (GE)/ml to 350 GE/ml and good overall tolerance of the
treatment. This patient is still being successfully treated with
TDF, and the HBV viral load is below the limit of detection
FIG. 1. Quasispecies analyses and alignments of four representative clones, each obtained from RT polymerase gene PCR amplificates before
and after therapy for patients 1 and 2. In total, up to 10 clones per patient were sequenced, and of those, 4 representative clones are shown in the
figure. Panel “a” indicates the sequences obtained before ADF therapy, whereas panel “b” indicates the sequences obtained after the increase of
viral load, i.e., during or immediately after ADF therapy.
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(10 IU/ml, or 50 GE/ml). This shows that patients with ADF-
resistant HBV can be successfully treated with TDF.
In the male patient, viremia also initially dropped from 4.5
107 GE/ml to 800 GE/ml and was undetectable 56 weeks after
start of TDF therapy. However, TDF therapy of the male
patient had to be stopped due to the emergence of drug-
induced renal toxicity. Consequently, HBV therapy was
switched to treatment with entecavir (Baraclude; Bristol Meyer
Squibb), which was recently licensed for HBV therapy. To our
surprise, the switch from TDF to entecavir resulted in a mod-
erate but remarkable increase in viremia, from below the limit
of detection to 104 GE/ml, while the rtI233V polymorphism
partially reverted to the wild type (rtI233V 3 rtI233V), as
shown by direct sequencing of PCR products. As the rtI233V
polymorphism was present before ADF therapy, this change to
rt233I might represent a novel form of counterselection in
which the naturally occurring resistance-associated rt233V
polymorphism is presumably selected and changed by TDF
therapy to wild-type rt233I. This observation may reflect the
response of the rtI233V variant HBV strains to TDF upon
inclusion of TDF in a therapy regimen that replaces ADF.
In the present report, we provide two independent lines of
evidence which suggest that the rtI233V HBV polymerase mu-
tation is indeed associated with ADF resistance as recently
described (2, 15). Moreover, we show for the first time that the
rtI233V mutation can be selected during ADF therapy in two
patients. In addition, the follow-up of previously reported pa-
tients infected with rtI233V HBV mutants revealed that the
cessation of ADF treatment can result in a loss of rtI233V and
its conversion to the wild type (rt233I). Interestingly, one of the
novel patients, patient 1, showed an initial response to ADF
that resulted in a decrease of about 4 log10 in viral load,
starting at 108 GE/ml and decreasing to 104 GE/ml, but the
viral load remained constantly high, at 104 GE/ml, for more
than 12 months (Fig. 2). Although a decrease of more than 1
log10 in viral load is considered a therapy success and the
reduced viremia may improve the further outcome of liver
disease, the decrease was relatively weak and viral replication
remained active at a relatively high level, which is corroborated
by increasing levels of HBsAg in the serum. Fluctuation of the
viremia should also be considered in this case, since it has been
shown that viremia may fluctuate about 1 log10 once chronic
infection has been established, as observed in the woodchuck
model (14). Since equivalent data from human patients has not
yet been published, it remains unclear whether the fluctuation
interval in humans may be more than 2 log steps and whether
a viral load decrease of 4 log10 should be rated as a therapy
success when viral load still remains high.
FIG. 2. Time course of viremia and HBsAg levels in two novel patients (patients 1 [a] and 2 [b]) for whom ADF therapy failed in association
with the rtI233V polymerase mutation.
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Moreover, these clinical cases give important insights into
new treatment options that may be investigated in clinical
studies in the future. First, it is worth noting that ADF can be
efficiently replaced with TDF, provided that no side effects,
such as nephrotoxicity, are observed. Thus, TDF is an efficient
HBV-suppressing drug in ADF nonresponders or rebounders,
although a cross-resistance between ADF and TDF was ini-
tially suspected. Second, the increase in viremia after replace-
ment of TDF with entecavir in patient 1 may be a hint that the
previous treatment primes for or even triggers entecavir resis-
tance. Although, according to Chang and Lai (3, 8), the viremia
in this patient may be considered low at a level of around 104
GE/ml, still, this level of viremia should be high enough to
allow for the selection and emergence of resistant strains.
We conclude that the rtI233V mutation in the HBV poly-
merase gene mediates ADF resistance, consistent with previ-
ous reports (2, 15). Our data are divergent from those reported
by Curtis et al. stating that the rtI233V mutation does not
confer resistance to ADF (4). The in vitro resistance phenotype
detection assay used by Curtis et al. is based on cytomegalo-
virus (CMV)-driven expression of the HBV genome and thus
produces a large excess of viral pregenomes, a parameter used
as a readout in their assay. Thus, CMV-driven in vitro systems
seem less sensitive than those involving viral replicons driven
by authentic promoters and thus seem inappropriate for mea-
suring the relative extents of susceptibility of RT mutant ge-
nomes to nucleoside or nucleotide analogues (10, 12, 16). Nev-
ertheless, the patients reported by Curtis and colleagues were
susceptible to ADF therapy in vivo despite the rtI233V muta-
tion. In the context of the data presented here, the hypotheses
that arise are (i) that HBV resistance mechanisms are much
more complicated than believed so far and (ii) that additional
factors of the host or the virus contribute to clinical and phe-
notypical resistance or dose-dependent resistance against a
distinct antiviral therapy.
Consequently, we recommend that in cases where the
rtI233V mutation is detectable, ADF should be replaced with
TDF or, with some limitations, with entecavir (3, 8).
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